Hakop Gevorkyan

435 total citations
12 papers, 301 citations indexed

About

Hakop Gevorkyan is a scholar working on Molecular Biology, Pharmacology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Hakop Gevorkyan has authored 12 papers receiving a total of 301 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Molecular Biology, 3 papers in Pharmacology and 3 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Hakop Gevorkyan's work include Monoclonal and Polyclonal Antibodies Research (3 papers), Neuroscience and Neuropharmacology Research (2 papers) and Receptor Mechanisms and Signaling (2 papers). Hakop Gevorkyan is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (3 papers), Neuroscience and Neuropharmacology Research (2 papers) and Receptor Mechanisms and Signaling (2 papers). Hakop Gevorkyan collaborates with scholars based in United States, United Kingdom and Japan. Hakop Gevorkyan's co-authors include Stanford S. Jhee, Iris Rajman, Markus Hinder, Thomas Langenickel, Surya Ayalasomayajula, Parasar Pal, Marie‐Anne Valentin, Edward J. Parr, Remko de Jong and Jitesh Rana and has published in prestigious journals such as Antimicrobial Agents and Chemotherapy, Annals of the Rheumatic Diseases and Psychopharmacology.

In The Last Decade

Hakop Gevorkyan

12 papers receiving 294 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hakop Gevorkyan United States	10	80	65	54	47	40	12	301
Yaoxian Liang China	12	53 0.7×	82 1.3×	35 0.6×	20 0.4×	69 1.7×	20	330
Shabaz A. Hamid United Kingdom	10	107 1.3×	136 2.1×	94 1.7×	55 1.2×	24 0.6×	12	336
А. V. Mukhomedzyanov Russia	10	134 1.7×	127 2.0×	154 2.9×	37 0.8×	29 0.7×	61	385
Carsten Stoetzer Germany	12	62 0.8×	136 2.1×	68 1.3×	99 2.1×	16 0.4×	20	398
Г. З. Суфианова Russia	11	51 0.6×	97 1.5×	56 1.0×	30 0.6×	8 0.2×	36	323
Zsolt Balla Hungary	12	17 0.2×	60 0.9×	31 0.6×	36 0.8×	18 0.5×	19	290
Xiaohong Du China	11	18 0.2×	149 2.3×	59 1.1×	31 0.7×	40 1.0×	20	341
Wichwara Nawara Thailand	11	72 0.9×	111 1.7×	22 0.4×	73 1.6×	12 0.3×	32	287
Parvaneh Keshavarz Iran	11	35 0.4×	163 2.5×	20 0.4×	41 0.9×	11 0.3×	38	361
Naoki Haruyama Japan	11	50 0.6×	101 1.6×	20 0.4×	130 2.8×	7 0.2×	30	402

Countries citing papers authored by Hakop Gevorkyan

Since Specialization

Citations

This map shows the geographic impact of Hakop Gevorkyan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hakop Gevorkyan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hakop Gevorkyan more than expected).

Fields of papers citing papers by Hakop Gevorkyan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hakop Gevorkyan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hakop Gevorkyan. The network helps show where Hakop Gevorkyan may publish in the future.

Co-authorship network of co-authors of Hakop Gevorkyan

This figure shows the co-authorship network connecting the top 25 collaborators of Hakop Gevorkyan. A scholar is included among the top collaborators of Hakop Gevorkyan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hakop Gevorkyan. Hakop Gevorkyan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Han, Kelong, Hakop Gevorkyan, Jafar Sadik Shaik, et al.. (2023). Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the vastus lateralis (lateral thigh) muscles of healthy adult participants. Antimicrobial Agents and Chemotherapy. 68(1). e0078123–e0078123. 14 indexed citations

Nakai, Kenya, Yasumi Kitahara, Seiichiro Hojo, et al.. (2022). First‐in‐Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742, a Dual Antagonist of Toll‐like Receptors 7 and 8, in Healthy Volunteers. Clinical Pharmacology in Drug Development. 12(4). 363–375. 15 indexed citations

Yin, Wei, Fahimeh Mamashli, Derek L. Buhl, et al.. (2021). Safety, pharmacokinetics and quantitative EEG modulation of TAK‐071, a novel muscarinic M1 receptor positive allosteric modulator, in healthy subjects. British Journal of Clinical Pharmacology. 88(2). 600–612. 13 indexed citations

Hikichi, Hirohiko, et al.. (2020). Safety and pharmacokinetic profiles of MGS0274 besylate (TS‐134), a novel metabotropic glutamate 2/3 receptor agonist prodrug, in healthy subjects. British Journal of Clinical Pharmacology. 86(11). 2286–2301. 11 indexed citations

Esfandiari, Ehsanollah, Hakop Gevorkyan, Hélène M. Faessel, et al.. (2018). SAT0226 A phase 1, randomized, double-blind, placebo-controlled, single- and multiple-rising dose study of the btk inhibitor tak-020 in healthy volunteers. Annals of the Rheumatic Diseases. 77. 974–974. 3 indexed citations

Baverel, Paul, Dewei She, Edward Piper, et al.. (2017). A randomized, placebo-controlled, single ascending-dose study to assess the safety, tolerability, pharmacokinetics, and immunogenicity of subcutaneous tralokinumab in Japanese healthy volunteers. Drug Metabolism and Pharmacokinetics. 33(3). 150–158. 15 indexed citations

Tsai, Max, et al.. (2016). A phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063, a selective PDE10A inhibitor. Psychopharmacology. 233(21-22). 3787–3795. 16 indexed citations

Willis, Brian A., Stephen L. Lowe, Robert A. Dean, et al.. (2016). P1‐044: Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of LY3202626, a Novel Bace1 Inhibitor, in Healthy Subjects and Patients with Alzheimer’s Disease. Alzheimer s & Dementia. 12(7S_Part_8). 7 indexed citations

Langenickel, Thomas, Surya Ayalasomayajula, Parasar Pal, et al.. (2015). The effect of LCZ696 (sacubitril/valsartan) on amyloid‐β concentrations in cerebrospinal fluid in healthy subjects. British Journal of Clinical Pharmacology. 81(5). 878–890. 82 indexed citations

10.

Tran, Jonathan Q., Jitesh Rana, Frederik Barkhof, et al.. (2014). Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033. Neurology Neuroimmunology & Neuroinflammation. 1(2). e18–e18. 99 indexed citations

11.

Katz, David A., C. Locke, Peer B. Jacobson, et al.. (2013). Peripheral and central nervous system inhibition of 11β-hydroxysteroid dehydrogenase type 1 in man by the novel inhibitor ABT-384. Translational Psychiatry. 3(8). e295–e295. 12 indexed citations

12.

Martényi, Ferenc, Robert A. Dean, Stephen L. Lowe, et al.. (2012). P3‐363: BACE inhibitor LY2886721 safety and central and peripheral PK and PD in healthy subjects (HSs). Alzheimer s & Dementia. 8(4S_Part_16). 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact